PMID- 29173270
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1911-6470 (Print)
IS  - 1920-1214 (Electronic)
IS  - 1911-6470 (Linking)
VI  - 12
IP  - 1
DP  - 2018 Jan
TI  - Clinical outcomes of the sequential use of pazopanib followed by everolimus for 
      the treatment of metastatic renal cell carcinoma: A multicentre study in Korea.
PG  - E15-E20
LID - 10.5489/cuaj.4644 [doi]
AB  - INTRODUCTION: The aim of this study was to investigate the real-world clinical 
      outcomes of first-line pazopanib and second-line everolimus in Korean patients 
      with metastatic renal cell carcinoma (mRCC). METHODS: Data of patients who had 
      mRCC with clear-cell component between 2001 and 2015 at multiple institutions 
      were collected retrospectively. To be included in the analysis, patients had to 
      meet the following criteria: age >/=18 years; received first-line targeted therapy 
      with pazopanib; and received second-line targeted therapy with everolimus. The 
      primary outcomes included overall survival (OS), progression-free survival (PFS), 
      and adverse events (AEs). RESULT: A total of 36 patients were included in the 
      analysis. The median followup period was 33.5 months (range 17-49.5). The median 
      PFS was eight months (95% confidence interval [CI] 6.4-9.6) after treatment with 
      pazopanib and three months (95% CI 1.9-4.1) with everolimus. The median OS was 27 
      months (95% CI 16.6-37.4). The median treatment duration was seven months (range 
      4.3-10.8) after treatment with pazopanib and 3.5 months (range 3-4) with 
      everolimus. Multivariate analysis revealed that the Heng risk criteria were 
      independently associated with OS (p<0.001). Almost every patient experienced some 
      form of AE, the majority of which were mostly mild or moderate in severity. The 
      most common AEs were diarrhea (50%), hypertension (44.4%), and fatigue (41.7%) 
      after treatment with pazopanib, and anemia (47.2%), stomatitis (41.7%), and 
      fatigue (38.9%) with everolimus. CONCLUSIONS: The outcomes for the patients 
      treated with pazopanib followed by everolimus in Korea as observed by us were 
      consistent with those reported by previous studies. The Heng risk criteria were 
      significantly associated with the prognosis of patients with mRCC. AEs were 
      mainly mild to moderate and readily managed.
FAU - Kim, Jeong Ho
AU  - Kim JH
AD  - Dongnam Institute of Radiological & Medical Sciences Cancer Centre, Korea.
FAU - Lee, Wan
AU  - Lee W
AD  - Dongnam Institute of Radiological & Medical Sciences Cancer Centre, Korea.
FAU - Kim, Tae Nam
AU  - Kim TN
AD  - Department of Urology, Pusan National University Hospital, Busan, Korea.
FAU - Nam, Jong Kil
AU  - Nam JK
AD  - Department of Urology, Pusan National University Hospital, Busan, Korea.
FAU - Kim, Tae Hyo
AU  - Kim TH
AD  - Department of Urology, Dong-A University Hospital, Busan; Korea.
FAU - Lee, Ki Soo
AU  - Lee KS
AD  - Department of Urology, Dong-A University Hospital, Busan; Korea.
LA  - eng
PT  - Journal Article
DEP - 20171201
PL  - Canada
TA  - Can Urol Assoc J
JT  - Canadian Urological Association journal = Journal de l'Association des urologues 
      du Canada
JID - 101312644
PMC - PMC5783702
COIS- Competing interests: The authors report no competing personal or financial 
      interests.
EDAT- 2017/11/28 06:00
MHDA- 2017/11/28 06:01
PMCR- 2018/01/01
CRDT- 2017/11/28 06:00
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2017/11/28 06:01 [medline]
PHST- 2017/11/28 06:00 [entrez]
PHST- 2018/01/01 00:00 [pmc-release]
AID - cuaj.4644 [pii]
AID - cuaj-1-e15 [pii]
AID - 10.5489/cuaj.4644 [doi]
PST - ppublish
SO  - Can Urol Assoc J. 2018 Jan;12(1):E15-E20. doi: 10.5489/cuaj.4644. Epub 2017 Dec 
      1.